How far have we come with bioresorbable vascular scaffolds, and where should we go?
Technical advances in percutaneous coronary intervention (PCI) have had huge impact on the treatment of coronary artery disease (CAD). Current guidelines recommend drug-eluting stent (DES) implantation as the standard care in CAD patients (1). However, even the newest generation DES have intrinsic limitations, such as the persistent risk of late stent failure, delayed chronic inflammation due to the polymer or metal components of stent, and loss of physiologic vasomotor function induced by the metal cage. Recently, BVS have emerged as an innovative tool to overcome the long-term complications of DESs. By applying a temporary scaffold, BVS provides adequate radial support to seal dissection, limit acute recoil and constrictive remodeling, whilst restoring normal vascular function after absorption.